Embla Medical hf. (EMBLA.CO)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 630 | 719 | 719 | 799 | 855 | 964 | 981 | 1,007 |
| Operating profit | $m | 129 | 138 | ||||||
| Net profit | $m | 6 | 64 | 43 | 58 | 68 | 86 | 94 | 99 |
| EPS reported | $ | 0.20 | 0.22 | ||||||
| Operating cashflow per share | $ | 0.33 | 0.34 | ||||||
| Capex per share | $ | 0.05 | 0.05 | ||||||
| FCF per share | $ | 0.28 | 0.29 | ||||||
| Free cash flow | $m | 119 | 128 | ||||||
| Net debt | $m | 258 | 261 | ||||||
| Book value equity | $m | 889 | 921 | ||||||
| Book value per share | $ | 2.08 | 2.14 | ||||||
| Number of shares | m | 427 | 429.78 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 25.50 | 20.24 | ||||||
| P/B LTM | x | 2.45 | 2.36 | ||||||
| P/S LTM | x | 2.26 | 2.22 | ||||||
| P/FCF LTM | x | 18.31 | 17.03 | ||||||
| EV/EBITDA LTM | x | 13.78 | 12.86 | ||||||
| EV/Sales LTM | x | 2.72 | 2.24 | ||||||
| Earnings Yield LTM | % | +3.92% | +4.94% | ||||||
| FCF Yield | % | +5.46% | +5.87% | ||||||
| Quality | |||||||||
| ROE | % | +9.73% | +10.47% | ||||||
| ROIC | % | +6.56% | +6.79% | ||||||
| Operating margin | % | +13.43% | +13.66% | ||||||
| Gross margin | % | +58.18% | +60.28% | ||||||
| FCF/Sales | % | +12.34% | +12.74% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +25.00% | +37.50% | ||||||
| Sales Growth YoY | % | +12.72% | +14.80% | ||||||
| Net Income Growth YoY | % | +26.64% | +37.37% | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | +14.75% | +22.50% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.22 | 0.24 | ||||||
| Net Debt/EBITDA | x | 2.31 | 2.14 | ||||||
| EBIT/Net interest | x | 5.91 | 6.33 | ||||||
| Net debt/market cap | % | +16.53% | +20.37% | ||||||
| Net debt/Equity | x | 0.29 | 0.28 | ||||||
| Gross debt/equity | x | 0.61 | 0.58 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics and Neuro Orthotics, Bracing and Supports, and Patient Care. The Prosthetics and Neuro Orthotics segment offers mechanical products, such as lower and upper limb loss or difference; and bionic products, such as microprocessor-controlled feet, knees, hands, fingers, and neuro orthotic joints. The Bracing and Supports segment provides osteoarthritis solutions that are designed to reduce pain and improve mobility for people living with osteoarthritis; and injury solutions for people recovering from fractures, ligament injuries, or need post-operative treatment. This segment also offers Unloader One, a range knee braces that relieve pain from knee osteoarthritis; and Unloader Hip, which is designed to reduce pain by optimizing load dispersion for patients suffering from mild and moderate osteoarthritis of the hip. The Patient Care segment provides prosthetics for people with lower and upper limb loss or limb difference; and orthotics for neurological, gait, and musculoskeletal conditions. The company serves orthopedic and prosthetic clinics, hospitals, and surgery centers. It sells its products through its direct sales networks and distributors. The company was formerly known as Össur hf. and changed its name to Embla Medical hf. in April 2024. Embla Medical hf. was incorporated in 1971 and is headquartered in Reykjavik, Iceland. Embla Medical hf. is a subsidiary of William Demant Invest A/S.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics and Neuro Orthotics, Bracing and Supports, and Patient Care. The Prosthetics and Neuro Orthotics segment offers mechanical products, such as lower and upper limb loss or difference; and bionic products, such as microprocessor-controlled feet, knees, hands, fingers, and neuro orthotic joints. The Bracing and Supports segment provides osteoarthritis solutions that are designed to reduce pain and improve mobility for people living with osteoarthritis; and injury solutions for people recovering from fractures, ligament injuries, or need post-operative treatment. This segment also offers Unloader One, a range knee braces that relieve pain from knee osteoarthritis; and Unloader Hip, which is designed to reduce pain by optimizing load dispersion for patients suffering from mild and moderate osteoarthritis of the hip. The Patient Care segment provides prosthetics for people with lower and upper limb loss or limb difference; and orthotics for neurological, gait, and musculoskeletal conditions. The company serves orthopedic and prosthetic clinics, hospitals, and surgery centers. It sells its products through its direct sales networks and distributors. The company was formerly known as Össur hf. and changed its name to Embla Medical hf. in April 2024. Embla Medical hf. was incorporated in 1971 and is headquartered in Reykjavik, Iceland. Embla Medical hf. is a subsidiary of William Demant Invest A/S.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free